Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 112 citing Jiang: Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among.... (0.09 sec) 

Adiponectin and future coronary heart disease events among men with type 2 …

- diabetesjournals.org
MB Schulze, I Shai, EB Rimm, T Li, N Rifai, FB Hu - Diabetes, 2005 - Am Diabetes Assoc
Adiponectin, predominantly synthesized in the adipose tissue, seems to have substantial
anti-inflammatory properties and to be a major modulator of insulin resistance and
dyslipidemia, mechanisms that are associated with an increased atherosclerotic risk in ...
Cited by 185 - Related articles - All 5 versions

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of …

- ahajournals.org
T Pischon, CJ Girman, FM Sacks, N Rifai, MJ Stampfer, … - Circulation, 2005 - Am Heart Assoc
From the Departments of Nutrition (TP, FMS, MJS, EBR) and Epidemiology (TP, MJS, EBR), Harvard
School of Public Health, Boston, Mass; Channing Laboratory (FMS, MJS, EBR), Department
of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass; ...
Cited by 158 - Related articles - All 7 versions

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: …


PJ Barter, CM Ballantyne, R Carmena, MC … - Journal of internal …, 2006 - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Cited by 143 - Related articles - BL Direct - All 7 versions

The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a …

- pubget.com [PDF] 
G Walldius, I Jungner - Journal of internal medicine, 2006 - pt.wkhealth.com
Correspondence: Göran Walldius, Astra Zeneca (ISMO), SE-151 85 Södertälje, Sweden.
(fax: +46 (0) 8 553 23157; e-mail: goran.walldius@astrazeneca.com). ... The rationale for using
apoB, apoA-I and the apoB... ... The apoB/apoA-I ratio versus lipid and lipoprotei...
Cited by 120 - Related articles - BL Direct - All 8 versions

Lipoprotein management in patients with cardiometabolic risk


JD Brunzell, M Davidson, CD Furberg, RB … - Diabetes Care, 2008 - Am Diabetes Assoc
Risk factors for type 2 diabetes and cardiovascular disease (CVD) often cluster, including obesity
(particularly central), insulin resistance, hyperglycemia, dyslipoproteinemia, and
hypertension. These conditions can also occur in isolation, and they are exaggerated by ...
Cited by 64 - Related articles - All 22 versions

A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for …

- nih.gov
G Tuncman, E Erbay, X Hom, I De Vivo, H … - Proceedings of the …, 2006 - National Acad Sciences
Obesity and the associated pathologies including dyslipidemia, insulin resistance, type 2
diabetes, and cardiovascular disease constitute a major threat to global human health. Yet, the
genetic factors that differentially predispose individuals to this cluster of pathologies are ...
Cited by 63 - Related articles - BL Direct - All 12 versions

Role of the apolipoprotein B-apolipoprotein AI ratio in cardiovascular risk …

- annals.org [PDF] 
WA van der Steeg, SM Boekholdt, EA Stein, … - Annals of Internal …, 2007 - Am Coll Physicians
Wim A. van der Steeg, MD; S. Matthijs Boekholdt, MD, PhD; Evan A. Stein, MD, PhD; Karim
El-Harchaoui, MD; Erik SG Stroes, MD, PhD; Manjinder S. Sandhu, PhD; Nicholas J.
Wareham, MBBS, PhD; J. Wouter Jukema, MD, PhD; Robert Luben, BSc; Aeilko H. ...
Cited by 61 - Related articles - BL Direct - All 3 versions

Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL …

- diabetesjournals.org [PDF] 
MB Schulze, K Hoffmann - Diabetes Care, 2005 - Am Diabetes Assoc
The National Cholesterol Education Program (NCEP) guidelines recom- mend use of statin-fibrate
combina- tions to treat combined dyslipidemia. Myopathy and rhabdomyolysis are re- ported
side effects, especially with gemfi- brozil-statin combinations (1). This risk is recognized to ...
Cited by 55 - Related articles - All 8 versions

Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk …


J Liu, C Sempos, RP Donahue, J Dorn, M Trevisan, … - Diabetes Care, 2005 - Am Diabetes Assoc
RESEARCH DESIGN AND METHODS—We used four publicly available data sets for this pooled
post hoc analysis and confined the eligible subjects to white individuals aged ≥30 years and
free of CHD at baseline (12,660 men and 6,721 women). Diabetes status was defined as ...
Cited by 54 - Related articles - BL Direct - All 6 versions

[CITATION] Lipoprotein management in patients with cardiometabolic risk: consensus …


JD Brunzell, M Davidson, CD Furberg, RB Goldberg, … - Diabetes Care, 2008 - ncbi.nlm.nih.gov
1: Diabetes Care. 2008 Apr;31(4):811-22. Lipoprotein management in patients with
cardiometabolic risk: consensus statement from the American Diabetes Association
and the American College of Cardiology Foundation. Brunzell ...
Cited by 53 - Related articles - BL Direct - All 2 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google